ARA-290 vs LL-37

A side-by-side comparison from PeptideSciences101, the open peptide reference.

Overview

ARA-290 is primarily a pain management peptide, while LL-37 is used for immune support.

This page compares ARA-290 and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

ARA-290LL-37
CategoryPain ManagementImmune Support
Regulatory status (US)Research use onlyCompounding (Rx) — Apr 2026
Typical dosage2-4 mg2-5 mg
Frequencydaily for cyclestwice weekly
Reported benefitsNeuropathic pain reduction, nerve protection, diabetic neuropathy supportAntimicrobial activity, immune modulation, wound healing, anti-inflammatory
Reported side effectsGenerally well-toleratedGenerally safe, minimal side effects

Key differences

Primary use. ARA-290 is categorised under Pain Management, while LL-37 falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.

Regulatory status. ARA-290: not FDA-approved; treated as a research compound. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026.

Dosing. ARA-290 is typically dosed at 2-4 mg (daily for cycles). LL-37 is typically dosed at 2-5 mg (twice weekly).

Can you stack them?

Some protocols combine peptides, but stacking ARA-290 and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between ARA-290 and LL-37?
ARA-290 is primarily a pain management peptide, while LL-37 is used for immune support. ARA-290 is not FDA-approved; generally classified as a research compound, whereas LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
What is ARA-290 used for?
Neuropathic pain specialist.
What is LL-37 used for?
Antimicrobial defense peptide.
Can you take ARA-290 and LL-37 together?
Some users combine peptides within a single protocol, but stacking ARA-290 and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
Is ARA-290 or LL-37 FDA-approved?
ARA-290 is not FDA-approved; generally classified as a research compound. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).

Read the full articles

  • ARA-290 — full monograph: mechanism, research, dosing & references
  • LL-37 — full monograph: mechanism, research, dosing & references

More Pain Management comparisons

← All peptide comparisons